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A Case of Combined Hepatocellular-Cholangiocarcinoma
with Favorable Response to Systemic Chemotherapy
I n t r o d u c t i o n
Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare
form of primary liver cancer composed of cells with histopathologic
features of both hepatocellular carcinoma (HCC) and cholangiocar-
cinoma (CC). It accounts for up to 14.3% of primary liver cancers,
with incidence varying between multiple studies (1-4). cHCC-CC was
first described in 1949 by Allen and Lisa (2), but the demographics
and clinical features of these tumors remain ill-defined. In addition,
the diagnostic features are not well established, which may have
contributed to the variability in clinical outcomes (1,3-5). To our
knowledge, surgery is the only treatment modality offering possibility
for a cure (6), and there are at present no published reports des-
cribing non-surgical treatment options for cHCC-CC. For patients
with disseminated disease, systemic chemotherapy may be an
option, but no known treatment to date has demonstrated any chance
of significantly improving survival. We report a case of cHCC-CC
exhibiting a favorable response to systemic chemotherapy with
doxorubicin and cisplatin.
C a s e  R e p o r t
A 62-year old man was admitted to our hospital for recurrence of
cHCC-CC. He was diagnosed as stage II HCC (T2N0M0) by tumor
marker and imaging study in February 2004. The patient did not
have any known risk factors for HCC and thus underwent a right
lobectomy at that time. Surgical pathologic report revealed cHCC-
CC (Fig. 1). Four years after the operation, a computed tomography
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Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare form of primary liver
cancer composed of cells with histopathologic features of both hepatocellular carcinoma
(HCC) and cholangiocarcinoma (CC). Because of its low incidence, the information on
clinical outcomes of cHCC-CC is very limited and there are no published reports describing
non-surgical treatment options for cHCC-CC. We report a case of cHCC-CC exhibiting a
favorable response to systemic chemotherapy with doxorubicin and cisplatin. A 62-year-old
man who recurred after a right lobectomy for cHCC-CC received sorafenib for palliative
systemic therapy, but follow up imaging studies showed disease progression. He received
2nd line chemotherapy with doxorubicin at 60 mg/m2 together with cisplatin at 70 mg/m2.
After 2 cycles of chemotherapy, a computed tomography scan of the chest showed
markedly decreased size and number of the multiple lung metastases. After completing 8
cycles of 2nd line therapy, we changed the regimen to a fluorouracil (5-FU) mono therapy
because of the toxicities associated with doxorubicin and cisplatin. To date, the patient has
completed his 15th cycle of 5-FU mono therapy with the disease status remaining stable
during 18 months of follow-up.
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(CT) scan of the chest showed multiple lung metastasis, along with
a whole body bone scan (WBBS) revealing multiple bone me-
tastasis (T-spine, rib, scapula). At the time of recurrence, laboratory
tests including a liver function test were normal and his overall
performance status was categorized as good. He received 1st line
palliative therapy with sorafenib from July 2008 to September 2008,
but a follow up imaging study showed disease progression with
further lung metastasis (Fig. 2) and a PIVKA-II elevated to more
than 2,000 mAU/mL.
He then received 2 cycles of palliative therapy with doxorubicin
and cisplatin (AC regimen, doxorubicin 60 mg/m2 day 1, cisplatin
70 mg/m2 day 1 of a 3-week cycle) as 2nd line treatment. 
Surprisingly, a CT scan of the chest after the 2nd cycle of therapy
showed markedly decreased size and number of his multiple
hematogenous lung metastases (Fig. 3) and in addition his PIVKA-
II returned to within normal range. After 6 more cycles of che-
motherapy, the maintenance of response was confirmed by follow
up imaging studies. Toxicities associated with the AC regimen
(grade 2 neutropenia and grade 2 neuropathy) were manageable
with supportive care.
After a total of 8 cycles of therapy with the AC regimen, he pre-
sented with a grade 3 neuropathy, but no symptomatic cardiac
function abnormalities. However, considering the accumulation
dose of doxorubicin and grade 3 neuropathy associated with cispla-
tin, we changed his regimen to intravenous fluorouracil (5-FU) mo-
no therapy (1,000 mg/m2 day 1 to 4 continuous infusion for a 3-
week cycle). To date, he has completed his 15th cycle of 5-FU mo-
no therapy with the disease status remaining stable during 18
months of follow-up.
D i s c u s s i o n
Almost all primary liver carcinomas are broadly classified as
either HCC, derived from hepatocytes, or CC, arising from intra-
hepatic bile duct epithelium. Cases involving both hepatocellular
and cholangiocellular components in the same tumor have been de-
signated as cHCC-CC. According to the World Health Organization
tumor classification system, cHCC-CC is defined as a tumor in
which both HCC and CC components coexist in either the same
tumor or the same liver (1,7). As HCC and CC differ in their clinical
characteristics including etiology and epidemiology, cHCC-CC is
thought to be a result of dual differentiation of hepatic precursor
cells toward hepatocytes and biliary epithelia based on
clinicopathologic studies (8).
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Fig. 2. The follow up imaging studies at disease progression after 2 cycles of sorafenib. (A) Whole body bone scan showed multiple uptakes in
T-spine, left scapula, ribs. (B) Chest radiograph showed bilateral multiple various sized lung nodules. (C) CT scan of chest showed innumerable
hematogenous lung metastasis.
Fig. 1. Pathologic features of the combined hepatocellular-cho-
langiocarcinoma. There were two components - hepatocellular ele-
ment showing bile production, an intercellular bile canaliculi, and a
cholangiocellular component showing mucin production or definite
gland formation. There was no transition from the hepatocellular
carcinoma (right) to the cholangiocarcinoma (left) (H&E, ×100).
Two histopathologic classification schemes for these tumors have
been described. Allen and Lisa classified cHCC-CC into the three
categories: 1) separate tumors, each composed of only one type of
cell; 2) contiguous tumors, each of a different cell type that may
mingle as they grow; and 3) individual lesions that have both types
of cells and are interpreted to have arisen from the same site (2).
Goodman et al. (1) also classified three types: 1) Type I or “collision
tumors”; 2) Type II or “transitional tumors”; 3) Type III or
“fibrolamellar tumors.” In our case, there is no transition from the
hepatocellular components to the cholangiocellular components and
thus we may define this case as type I or collision tumors (Fig. 1).
The incidence of cHCC-CC varies between studies, as 1.0 to
6.3% in Asia (3,8-10) and 2.4 to 14.3% in Western countries (1-4).
Because of its low incidence, information on the prognosis of
patients with cHCC-CC is very limited and the reported clinical
outcomes vary and may not accurately represent the actual
prognosis of patients with cHCC-CC (3,5,6).
Surgery is the only treatment offering the possibility of a cure at
the present time (6). However, commonly combined liver cirrhosis
has the potential for serious complications, so strict selection of
patients is required, taking into consideration any pre-existing
cirrhosis, general physical condition, tumor extent as examples
(6,11,12). Currently, aggressive treatments including liver transplan-
tation have been attempted on cHCC-CC patient (13). However,
further data regarding long term outcomes with liver transplantation
in the treatment of cHCC-CC is required.
Transarterial chemoembolization (TACE) and percutaneous
treatments such as percutaneous ethanol injection (PEI) and radio-
frequency ablation (RFA) are the most widely used management
treatments for unresectable HCC and post resection recurrence.
However, to our knowledge, cHCC-CCs are more fibrotic and less
vascular than HCC (14). As a result, they are less responsive to local
treatments like TACE or PEI (15). For disseminated disease, systemic
chemotherapy may be an option, but there is little data supporting its
role in the treatment against cHCC-CC.
In our case, the patient was diagnosed with cHCC-CC after a
right lobectomy was performed for a liver mass. After a 4-year post-
operative period, cHCC-CC recurred presenting as multiple lung
metastasis with high levels of PIVKA-II. The patient first received
sorafenib as a 1st line palliative therapy, but the disease was refrac-
tory to this chemotherapy.  We then chose a combination of doxoru-
bicin and cisplatin as a 2nd line chemotherapeutic regimen with
favorable results as almost all multiple lung nodules disappeared.
After completing 8 cycles of therapy with the AC regimen, he was
then amended to receive 15 cycles of 5-FU mono therapy due to the
toxicities associated with AC. This long period of disease control is
a very encouraging result and requires further investigation in
clinical trials.
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